B of A Securities Reiterates Buy Rating on Jazz Pharmaceuticals

B of A Securities reiterated its buy rating on Jazz Pharmaceuticals (NasdaqGS: JAZZ) on June 10, 2026, setting a price target of $307. Analyst Jason Gerberry expressed continued confidence in the stock, which recently traded around $230.56.

Jazz Pharmaceuticals Stock Snapshot

Shares of Jazz Pharmaceuticals are currently trading at $230.56 on the NasdaqGS. The company has a market cap of approximately $14.48 billion and a forward P/E ratio of about 9.0. Jazz's stock has a 52-week range between $105.00 and $243.32, with a 50-day moving average of $217.29 and a 200-day moving average of $173.04. The company maintains a current ratio of 2.04 and a quick ratio of 1.65, with a debt-to-equity ratio of 119.52.

Recent Earnings

In its most recent financial report, Jazz Pharmaceuticals reported revenue of approximately $4.44 billion, with a revenue growth rate of 19.1%. The company's net margin stood at 0.66%, while return on equity was 0.68%. Jazz is expected to announce its next earnings on May 5, 2026.

Insider Buying and Selling at Jazz Pharmaceuticals plc

Several insiders at Jazz Pharmaceuticals have made planned sales recently. On June 10, 2026, Neena Patil, EVP & Chief Legal Officer, sold 1,200 shares at an average price of $231.83. Earlier, on June 1, 2026, Bruce Cozadd sold 6,000 shares at $235.12 under a planned transaction.

Analysts Set New Price Targets

On June 10, 2026, B of A Securities maintained its buy rating on Jazz Pharmaceuticals with a price target of $307. Barclays also maintained a buy rating with a $253 target on May 27, 2026. UBS upgraded Jazz to a buy with a $307 target on May 19, 2026. Overall, the consensus among 19 analysts is a buy rating, with an average price target of $255.95.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, headquartered in Dublin, Ireland, is a global biopharmaceutical company. It focuses on developing and marketing pharmaceutical products for various medical conditions, including sleep disorders and cancer. Led by CEO Renee D. Gala, Jazz Pharmaceuticals employs around 2,890 people. Its key products include Xywav, Epidiolex, and Rylaze, among others.

Bottom Line

B of A Securities' reiteration of its buy rating on Jazz Pharmaceuticals underscores continued optimism for the company's future performance. With a solid market position and a diverse product portfolio, Jazz Pharmaceuticals remains a significant player in the biotechnology sector. Investors should note that analyst ratings are one of many factors to consider, and this 13F filing reflects data as of the reporting period.